TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28135150
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon α-2b
Study: 18179609
Drug: Itopride (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride (200 mg t.i.d. for 7 days)
Study: 12649510
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment (control group)
Study: 2058589
Drug: Atole (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atole (moderate energy supplement)
Study: 2058589
Drug: Fresco (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresco (low energy supplement)
Study: 2058589
Drug: High-Atole group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Atole group (consumed >= 10% of daily RDI from supplement)
Study: 6202387
Drug: Concurrent immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent immunotherapy with the methanol extraction residue of bacillus Calmette‐Guerin (MER)
Study: 31539073
Drug: RightRx intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RightRx intervention (electronic medication reconciliation)
Study: 29413138
Drug: Video-Feedback Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-Feedback Therapy (VFT)
Study: 22114904
Drug: Albendazole (ABZ)
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole (ABZ) 400 mg daily for 5 days
Study: 22114904
Drug: Metronidazole (MTZ)
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (MTZ) 250 mg t.i.d. for 5 days
Study: 15853564
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lipid-lowering therapy)
Study: 9184602
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year treatment (group I)
Study: 9184602
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years treatment (group II)
Study: 8267059
Drug: Norethindrone 1
Normalized name: norethindrone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone 1 mg alone
Study: 3162058
Drug: Insulin-dependent treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-dependent treatment (group III)
Study: 25338680
Drug: Placebo (okara
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (okara powder, 2 g/d)
Study: 24136378
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (0.1 μg kg min) and preoperative isotonic saline (n=15)
Study: 24136378
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (0.2 μg kg min, increased to clinical demand) and preoperative saline (n=17)
Study: 24136378
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (0.2 μg kg min, increased to clinical demand) and preoperative amantadine (200 mg/500 ml) (n=16)
Study: 15310314
Drug: 30% fructose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% fructose solution (0.5 mL)
Study: 15310314
Drug: 30% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% glucose solution (0.5 mL)
Study: 15310314
Drug: Placebo (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile water, 0.5 mL)
Study: 11669411
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg and then 8 mg daily)
Study: 8149571
Drug: Disinfection solutions
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disinfection solutions (three different systems)
Study: 3146553
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin 10 mg/24 hours
Study: 31309323
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate supplementation (CHO)
Study: 28592751
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (atorvastatin 10‐20 mg and ezetimibe 10 mg/day; Group C)
Study: 28592751
Drug: Statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin monotherapy (atorvastatin 10‐20 mg; Group M)
Study: 20084878
Drug: Freeze-dried live
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried live attenuated varicella vaccine
Study: 15461825
Drug: Morphine 0.2
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.2 mg/kg IV
Study: 14606018
Drug: Endoscopic features
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic features (alone or in combination)
Study: 11189671
Drug: Weekly 2-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly 2-hour visit and walk by volunteers for 9 months (experimental group)
Study: 2865292
Drug: Cephazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephazolin (1 g)
Study: 2865292
Drug: Cefotetan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (1 g)
Study: 21448709
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (vitamin C) 2 g during myomectomy
Study: 12708881
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure lowering with perindopril 2mg/indapamide 0.625 mg then perindopril 4 mg/indapamide 1.25mg
Study: 12708881
Drug: Usual guidelines‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual guidelines‐based therapy
Study: 9885791
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (subanesthetic doses)
Study: 8574629
Drug: Intravenous urograms
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urograms in urology department patients
Study: 7128954
Drug: Keto analogs
Normalized name: Keto-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keto analogs of branched-chain amino acids (15.24 g orally over 4 weeks)
Study: 31534016
Drug: HVTN 097
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVTN 097 vaccine regimen
Study: 31534016
Drug: RV144 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV144 vaccine regimen
Study: 23907810
Drug: AZD3199 (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3199 (480 µg)
Study: 23907810
Drug: AZD3199 (1920
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3199 (1920 µg)
Study: 23907810
Drug: Formoterol (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (36 µg)
Study: 23907810
Drug: AZD3199 (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3199 (480 µg) and 1920 µg
Study: 21543191
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT) with Rehacom® software, n=8
Study: 20082253
Drug: Gubitong Recipe
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gubitong Recipe (GBT) Decoction, one dose every day for eight weeks
Study: 20082253
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate 500 mg thrice a day for eight weeks (Control)
Study: 11180037
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of fluvoxamine per day for 5 days
Study: 11180037
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of fluvoxamine per day for 5 days
Study: 7986789
Drug: Raw frozen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw frozen, blanched or canned carrots (15 g dietary fibre/d)
Study: 7986789
Drug: Raw or
Normalized name: raw sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw or raw frozen carrots (15 g dietary fibre/d)
Study: 7353190
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg by mouth
Study: 17150279
Drug: CTLA4 haplotypes
Normalized name: Anti-ctla4 mab (biocad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTLA4 haplotypes in male end-of-treatment responders
Study: 17150279
Drug: Interferon-alpha monotherapy
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha monotherapy or infection with HCV genotypes 1/4
Study: 8884559
Drug: cilazapril (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (5-10 mg/day)
Study: 8884559
Drug: nifedipine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (20-40 mg slow-release three times a day)
Study: 8884559
Drug: cilazapril (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (5-10 mg/day) in diabetic patients
Study: 1304463
Drug: CEE3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE3 (2 mg orally every 2 weeks)
Study: 3982576
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of calcium carbonate (mean 9 +/- 5 g/day)
Study: 25558030
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage (15-minute gentle abdominal massage, administered twice daily for 3 days)
Study: 25558030
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (twice-daily 15-minute social interaction contact with the same nurse)
Study: 23667615
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (fluticasone) for 30 months
Study: 19755551
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shockwave treatment: one session weekly for four to six weeks
Study: 19755551
Drug: Supervised exercises:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercises: two 45 minute sessions weekly for up to 12 weeks
Study: 14756388
Drug: Perfalgan 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfalgan 1 g
Study: 14756388
Drug: Perfalgan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfalgan 0.5 g
Study: 11318774
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (1200 microg dose)
Study: 28639542
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate MDPI (100 or 200 μg)
Study: 28639542
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol MDPI (100 μg/12.5 μg or 200 μg/12.5 μg)
Study: 28639542
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol MDPI (100 μg/12.5 μg)
Study: 22766525
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg
Study: 22766525
Drug: Budesonide 15
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 15 mg
Study: 7826564
Drug: Monatepil monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monatepil monotherapy (30 mg/day initially, titrated to 60 mg/day)
Study: 7826564
Drug: Monatepil in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monatepil in combination with ACE inhibitors (15 mg/day initially, titrated to 60 mg/day)
Study: 7826564
Drug: Monatepil in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monatepil in combination with beta-blockers (15 mg/day initially, titrated to 60 mg/day)
Study: 3417080
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine at 19.00 h
Study: 3417080
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine at 22.00 h
Study: 7015020
Drug: Cephalothin (antibiotic)
DrugBank: Cefalotin (DB00456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cephalothin (antibiotic)
Study: 31092196
Drug: RB stock
Normalized name: Rubidium Rb-82
DrugBank: Rubidium Rb-82 (DB09479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RB stock solution 10 mg/ml (Group 1)
Study: 31092196
Drug: Two-fold dilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-fold dilution 5 mg/ml (Group 2)
Study: 31092196
Drug: Three-fold dilution
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-fold dilution 3.3 mg/ml (Group 3)
Study: 25820113
Drug: Nebulization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of ropivacaine 150 mg before surgery
Study: 25820113
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of ropivacaine 150 mg before surgery
Study: 21806591
Drug: Multimodal analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesic protocol (n=47)
Study: 15343588
Drug: Exenatide-primed arm
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide-primed arm (subcutaneous exenatide starting at 0.02 micro g/kg TID, increasing every 3 days for 35 days)
Study: 11156782
Drug: Combined intraarterial/intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intraarterial/intravenous thrombolysis with 50 mg actilyse (maximal dose, 0.7 mg/kg)
Study: 9797806
Drug: Combined multimodal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined multimodal therapy (surgery and/or radiotherapy with chemotherapy)
Study: 7639376
Drug: Intravenous butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous butorphanol 30 micrograms/kg
Study: 7639376
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 60 micrograms/kg
Study: 18437173
Drug: Androgen ablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen ablation therapy
Study: 18437173
Drug: Novel therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel therapies (kinase inhibitors, antisense oligonucleotides, inhibitors of heat-shock proteins)
Study: 16088404
Drug: BOP in
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOP in responders not receiving interferon maintenance therapy
Study: 11783329
Drug: Xinyikang Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinyikang Oral Liquid (XYK)
Study: 11783329
Drug: Qidong Yixin
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qidong Yixin oral liquid
Study: 3541948
Drug: BCG immunisation
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunisation therapy
Study: 31421110
Drug: Orvepitant 30
Normalized name: Orvepitant
DrugBank: Orvepitant (DB12427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orvepitant 30 mg once daily for 4 weeks
Study: 28886575
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy with normative feedback
Study: 24290415
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of miglitol (100 mg)
Study: 24290415
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of miglitol (100 mg)
Study: 23739513
Drug: Cerebrolysin (monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (monotherapy, daily dosage 0.1 ml/kg, in the morning hours, on each other day, i.m., 30 injections in total) during 2 months
Study: 20978446
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus matuzumab (800 mg weekly)
Study: 20978446
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus matuzumab (1600 mg every 3 weeks)
Study: 12844130
Drug: 1 to
Normalized name: Cep-11981 tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 300 pmol/min vasopressin administered by the intrabrachial route
Study: 12844130
Drug: 300 pmol/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 pmol/min vasopressin administered by the intrabrachial route
Study: 12844130
Drug: Prolonged continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged continuous infusion of vasopressin
Study: 12844130
Drug: Vasopressin with
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin with nitric oxide clamp (4 micromol/min L‐N(G)‐monomethylarginine and 0.3 to 0.8 nmol/min sodium nitroprusside)
Study: 26179569
Drug: Diabetes Prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes Prevention Program lifestyle intervention (n = 30) consisting of 12 bi‐weekly core sessions and six monthly post‐core sessions
Study: 20119647
Drug: PTX3 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTX3 levels measured daily for 7 days and then at days 9, 11, 13, 18, 23, and 28.
Study: 11994055
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (3.2 mg kg‐1 on day 0 and 1.6 mg kg‐1 on days 1‐4)
Study: 11994055
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (3.2 mg kg‐1 on day 0 and 0.8 mg kg‐1 on days 1‐4)
Study: 11994055
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment R (artemether: 3.2 mg kg‐1 on day 0 and 0.8 mg kg‐1 on days 1‐4)
Study: 11994055
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (1.6 mg kg‐1 on day 0 and 0.8 mg kg‐1 on days 1‐4)
Study: 11994055
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment R
Study: 10424739
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan with high-fat breakfast
Study: 10424739
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan without food
Study: 10424739
Drug: Intravenous topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous topotecan
Study: 10424739
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan (fasted)
Study: 7844666
Drug: PRP-OMP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-OMP vaccine after first dose
Study: 7844666
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine after two doses
Study: 7844666
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine after three doses
Study: 18007263
Drug: Enteral supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral supplement (500 mL of Intestamin, Fresenius Kabi) containing conditionally essential nutrients
Study: 18007263
Drug: Enteral supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral supplement
Study: 16420512
Drug: 48-week peginterferon-alpha-2b
Normalized name: peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48-week peginterferon-alpha-2b (80-100 mcg/week) plus ribavirin (1000-1200 mg/day)
Study: 16420512
Drug: 24-week peginterferon-alpha-2b
Normalized name: peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-week peginterferon-alpha-2b (80-100 mcg/week) plus ribavirin (1000-1200 mg/day)
Study: 12830603
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter plus titrated oral misoprostol solution
Study: 12830603
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral misoprostol solution alone
Study: 1486157
Drug: Delayed-release indomethacin
Normalized name: indomethacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release indomethacin (Eudragit L formulation)
Study: 27731828
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium 50 mg test (F4) tablet formulation
Study: 24815497
Drug: Indomethacin (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (nonselective COX inhibitor)
Study: 24815497
Drug: Celebrex (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celebrex (selective COX-2 inhibitor)
Study: 10403615
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sinitrodil
Study: 10403615
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sinitrodil
Study: 10403615
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg sinitrodil
Study: 31570246
Drug: Postoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative chemoradiation therapy (CRT)
Study: 31570246
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy alone
Study: 23968769
Drug: rWN/DEN4Δ30 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rWN/DEN4Δ30 vaccine at 10³ PFU
Study: 23968769
Drug: rWN/DEN4Δ30 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rWN/DEN4Δ30 vaccine at 10⁴ PFU
Study: 23968769
Drug: rWN/DEN4Δ30 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rWN/DEN4Δ30 vaccine at 10⁵ PFU